Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2021 07:00 ET | Source: Aravive, Inc.

Aravive to Participate in Upcoming Virtual Investor Conferences in March

HOUSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and...
February 16, 2021 07:00 ET | Source: Aravive, Inc.

Aravive Announces $21.0 Million Registered Direct Offering with Eshelman Ventures, LLC Priced At-The-Market

HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that it has entered into a...
January 04, 2021 16:05 ET | Source: Aravive, Inc.

Aravive to Present at the H.C. Wainwright Virtual BioConnect Conference

HOUSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present at the...
December 31, 2020 19:00 ET | Source: Aravive, Inc.

Aravive Announces Board Member Transition to Advisory Role

HOUSTON, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that Dr. Ray Tabibiazar will be...
November 19, 2020 07:00 ET | Source: Aravive, Inc.

Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer

HOUSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company has received guidance...
November 16, 2020 16:05 ET | Source: Aravive, Inc.

Aravive to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

HOUSTON, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present and...
November 10, 2020 16:05 ET | Source: Aravive, Inc.

Aravive to Host Virtual Expert Event Focused on Ovarian and Renal Cancer on November 20, 2020

HOUSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will host a virtual...
November 10, 2020 07:00 ET | Source: Aravive, Inc.

Aravive and 3D Medicines Announce Strategic Collaboration to Develop and Commercialize AVB-500 in Greater China

Aravive to Receive $12 Million Signing Payment, up to an Additional $207 Million in Future Milestone Payments plus Tiered Royalties 3D Medicines to Lead Clinical Development and Commercialization of...
November 05, 2020 16:05 ET | Source: Aravive, Inc.

Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

Company expects to initiate pivotal trial of AVB-500 in Platinum Resistant Ovarian Cancer during fourth quarter 2020/first quarter 2021, based on Phase 1b resultsOn-track to initiate Phase 1b/2 trial...
September 17, 2020 07:00 ET | Source: Aravive, Inc.

Aravive Appoints Michael W. Rogers to Board of Directors

HOUSTON, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing transformative therapeutics, today announced that Michael W. Rogers...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right